Use of antidepressants by pregnant women: Evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making
- 17 June 2005
- journal article
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 8 (4) , 214-220
- https://doi.org/10.1007/s00737-005-0094-8
Abstract
Background: The World Health Organization predicts that by 2012, depression will be the number one disease in the world. Thus, many women who become pregnant will require treatment with antidepressants. We are aware that women and their health care providers remain hesitant to prescribe and take these drugs during pregnancy, despite evidence of the relative safety. Objectives: 1) To determine perception of risk of antidepressant drugs by pregnant women with depression, 2) to determine the efficacy of evidence-based counseling, and 3) to identify determinants that influence women in their decision making regarding the continuation/discontinuation of antidepressants during pregnancy. Methods: Women who called The Motherisk Program requesting information about the safety of an antidepressant during pregnancy were compared with two other groups: 1) Women who called about antibiotic use (i.e., non-teratogenic drugs used short-term) and 2) women who called about gastric medications (i.e., non-teratogenic drugs used long-term). Their perception of risk was measured before and after evidenced-based information was given and determinants of decision making was also evaluated. Results: We recruited 100 women taking antidepressants during pregnancy and 100 in each comparison group. Despite receiving evidence-based reassuring information, 15% of antidepressant users, compared to 4% using gastric drugs and 1% using antibiotics, chose to discontinue their medication. The main determinants of decision making were based on: information received prior to calling Motherisk, family and friends advice, the internet, sequence of advice given and if a women was undecided at the time of call. Conclusions: Women continue to fear taking antidepressants during pregnancy, more so than non psychiatric drugs, however, evidence based counseling can lower this fear, although not totally. Deciding whether to continue to take a medication or not during pregnancy, is a complex decision for women and their healthcare providers to make.Keywords
This publication has 12 references indexed in Scilit:
- Depressive Symptoms among Pregnant Women Screened in Obstetrics SettingsJournal of Women's Health, 2003
- A Multicentre Prospective Controlled Study to Determine the Safety of Trazodone and Nefazodone Use during PregnancyThe Canadian Journal of Psychiatry, 2003
- Pregnancy Outcome Following Gestational Exposure to Venlafaxine: A Multicenter Prospective Controlled StudyAmerican Journal of Psychiatry, 2001
- Antepartum Depressive Symptomatology Is Associated With Adverse Obstetric and Neonatal OutcomesPsychosomatic Medicine, 2001
- Associations among maternal depressive symptomatology, state of mind and parent and child behaviors: Implications for attachment-based interventionsAttachment & Human Development, 2001
- Pregnancy Outcome Following Maternal Use of the New Selective Serotonin Reuptake InhibitorsJAMA, 1998
- Neurodevelopment of Children Exposed in Utero to Antidepressant DrugsNew England Journal of Medicine, 1997
- Birth Outcomes in Pregnant Women Taking FluoxetineNew England Journal of Medicine, 1996
- The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS)Reproductive Toxicology, 1996
- Maternal Depressive Symptoms and the Risk of Poor Pregnancy OutcomeEpidemiologic Reviews, 1995